CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 4 enrolled
Drug / intervention
L-carnitinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00922701
NCT00922701Phase 2Completed
CompareCT.gov

Phase 2 Study of Dialysis Efficiency and Tolerability of Nocturnal Peritoneal Dialysis Solution Containing Glucose Plus L-carnitine

Iperboreal Pharma Srl·interventional·Posted Jun 17, 2009·Updated Feb 23, 2010

In Brief

A Phase 2 clinical trial evaluating L-carnitine for End-Stage Renal Disease. Completed, enrolled 4 participants across 1 site.

Detailed Summary

The development of glucose-sparing strategies able to provide an efficacious ultrafiltration profile represents one of the modern goals of peritoneal dialysis therapy. The study hypothesis is to evaluate the possibility to formulate peritoneal dialysis solutions containing L-carnitine as an osmotic agent to partially replace glucose.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd-Stage Renal Disease
CountriesItaly
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 17, 2009
Enrollment StartJun 1, 2004
Primary CompletionOct 1, 2004
Study CompletionDec 1, 2004
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 17.0 years ago

Interventions

L-carnitinedrug

Instillation of glucose-based (1.5% weight/volume) peritoneal dialysis solution containing L-carnitine (0.25% weight/volume) for the nocturnal exchange. Patients were treated with the experimental peritoneal dialysis solution for 5 days.